$ANIP
ANI PHARMACEUTICALS INC Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415062504 Filed on November 03, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$19.97M	$21.04M	$17.39M
YoY Change	14.87%	99.78%	121.89%
Cost Of Revenue	$3.260M	$3.670M	$3.061M
YoY Change	6.5%	26.12%	12.95%
Gross Profit	$16.71M	$17.36M	$14.33M
YoY Change	16.66%	127.82%	179.48%
Gross Profit Margin	83.68%	82.52%	82.39%
Selling, General & Admin	$5.399M	$4.740M	$4.057M
YoY Change	33.08%	48.13%	16.58%
% of Gross Profit	32.31%	27.3%	28.32%
Research & Development	$815.0K	$570.0K	$883.0K
YoY Change	-7.7%	9.62%	94.49%
% of Gross Profit	4.88%	3.28%	6.16%
Depreciation & Amortization	$2.047M	$1.280M	$1.187M
YoY Change	72.45%	190.91%	210.73%
% of Gross Profit	12.25%	7.37%	8.29%
Operating Expenses	$6.214M	$6.600M	$4.940M
YoY Change	25.79%	58.65%	25.57%
Operating Profit	$8.451M	$10.77M	$8.199M
YoY Change	3.07%	211.33%	912.22%
Interest Expense	-$2.766M	-$800.0K	$10.00K
YoY Change	-27760.0%
% of Operating Profit	-32.73%	-7.43%	0.12%
Other Income/Expense, Net	-$28.00K	$90.00K	$82.00K
YoY Change	-134.15%	200.0%	-44.59%
Pretax Income	$5.657M	$10.06M	$8.291M
YoY Change	-31.77%	188.25%	765.45%
Income Tax	$1.098M	-$10.95M	$1.545M
% Of Pretax Income	19.41%	-108.85%	18.63%
Net Earnings	$4.559M	$21.01M	$6.746M
YoY Change	-32.42%	512.54%	466.41%
Net Earnings / Revenue	22.83%	99.87%	38.8%
Basic Earnings Per Share	$0.40	$1.85	$0.59
Diluted Earnings Per Share	$0.39	$1.82	$0.59
COMMON SHARES
Basic Shares Outstanding	11.38M shares		11.24M shares
Diluted Shares Outstanding			11.30M shares

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$150.9M	$169.0M	$35.10M
YoY Change	329.91%	1422.52%	222.02%
Cash & Equivalents	$150.9M	$169.0M	$35.05M
Short-Term Investments
Other Short-Term Assets	$10.30M	$1.100M	$600.0K
YoY Change	1616.67%	83.33%	-79.31%
Inventory	$13.70M	$7.518M	$7.346M
Prepaid Expenses	$1.985M	$1.139M	$599.0K
Receivables	$21.60M	$17.30M	$14.57M
Other Receivables	$1.000M	$0.00	$0.00
Total Short-Term Assets	$197.5M	$195.0M	$57.57M
YoY Change	243.13%	603.53%	120.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.833M	$5.223M	$5.046M
YoY Change	15.6%	15.12%	8.74%
Goodwill		$1.838M	$1.838M
YoY Change		0.0%	-0.02%
Intangibles		$42.07M	$43.19M
YoY Change		304.14%	303.16%
Long-Term Investments
YoY Change
Other Assets	$9.800M	$15.40M
YoY Change
Total Long-Term Assets	$85.78M	$68.72M	$50.07M
YoY Change	71.31%	309.43%	191.27%
TOTAL ASSETS
Total Short-Term Assets	$197.5M	$195.0M	$57.57M
Total Long-Term Assets	$85.78M	$68.72M	$50.07M
Total Assets	$283.3M	$263.7M	$107.6M
YoY Change	163.2%	492.6%	148.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.600M	$2.654M	$3.059M
YoY Change	-15.0%	85.72%	46.58%
Accrued Expenses	$2.221M	$1.269M	$3.888M
YoY Change	-42.88%	-4.3%	190.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.19M	$13.23M	$8.145M
YoY Change	49.66%	274.02%	23.46%
LONG-TERM LIABILITIES
Long-Term Debt	$115.2M	$106.5M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$115.2M	$106.5M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.19M	$13.23M	$8.145M
Total Long-Term Liabilities	$115.2M	$106.5M	$0.00
Total Liabilities	$127.4M	$119.8M	$8.100M
YoY Change	1472.63%	3285.33%	22.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.226M	-$19.73M	-$40.73M
YoY Change	-82.26%	-59.31%	-21.53%
Common Stock	$1.000K	$1.000K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Treasury Stock Shares	0.000 shares	0.000 shares	0.000 shares
Shareholders Equity	$155.9M	$139.8M	$99.49M
YoY Change
Total Liabilities & Shareholders Equity	$283.3M	$259.6M	$107.6M
YoY Change	163.18%	483.28%	148.67%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	$4.559M	$21.01M	$6.746M
YoY Change	-32.42%	512.54%	466.41%
Depreciation, Depletion And Amortization	$2.047M	$1.280M	$1.187M
YoY Change	72.45%	190.91%	210.73%
Cash From Operating Activities	$10.23M	$10.74M	$4.160M
YoY Change	145.91%	-475.52%	-355.21%
INVESTING ACTIVITIES
Capital Expenditures	-$770.0K	-$340.0K	-$410.0K
YoY Change	87.8%	1033.33%	1266.67%
Acquisitions
YoY Change
Other Investing Activities	-$26.00M	$0.00	-$22.11M
YoY Change	17.59%	-100.0%
Cash From Investing Activities	-$26.77M	-$330.0K	-$22.53M
YoY Change	18.82%	-114.8%	75000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	710.0K	123.6M	460.0K
YoY Change	54.35%	15156.79%
NET CHANGE
Cash From Operating Activities	10.23M	10.74M	4.160M
Cash From Investing Activities	-26.77M	-330.0K	-22.53M
Cash From Financing Activities	710.0K	123.6M	460.0K
Net Change In Cash	-15.83M	134.0M	-17.91M
YoY Change	-11.61%	74338.89%	978.92%
FREE CASH FLOW
Cash From Operating Activities	$10.23M	$10.74M	$4.160M
Capital Expenditures	-$770.0K	-$340.0K	-$410.0K
Free Cash Flow	$11.00M	$11.08M	$4.570M
YoY Change	140.7%	-491.52%	-385.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1985000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1983000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	197522000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17297000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169037000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	3260000	USD
CY2014Q3	us-gaap	Revenues Revenues	17387000	USD
	us-gaap	Revenues Revenues	58287000	USD
	us-gaap	Revenues Revenues	34933000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	3061000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	7518000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	8266000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	7643000	USD
CY2015Q3	us-gaap	Prepaid Taxes PrepaidTaxes	972000	USD
CY2014Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
CY2015Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2674000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3307000	USD
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	163118000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159509000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7226000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19725000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	155893000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	139785000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	283276000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	263709000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	127383000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	123924000	USD
CY2015Q3	us-gaap	Revenues Revenues	19972000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	7800000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	883000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2213000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2110000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5399000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4057000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15701000	USD
CY2015Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2047000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2596000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	9188000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	31855000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	25699000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	8451000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	8199000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	26432000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	9234000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2766000	USD
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8240000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	13000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	82000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	40000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	72000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5657000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8291000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18232000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9319000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1098000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1545000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5733000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	4559000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	6746000	USD
	us-gaap	Net Income Loss NetIncomeLoss	12499000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	203478000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5223000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5833000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	11521000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13193000	USD
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1187000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4789000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	7118000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	9152000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	815000	USD
CY2015Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4253000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	7796000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2221000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1269000	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1019000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1348000	USD
CY2015Q3	anip	Accrued Medicaid Rebates AccruedMedicaidRebates	4428000	USD
CY2014Q4	anip	Accrued Medicaid Rebates AccruedMedicaidRebates	2264000	USD
CY2015Q3	anip	Returned Goods Reserve ReturnedGoodsReserve	1889000	USD
CY2014Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	1445000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12190000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13233000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2015Q3	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2014Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28000	USD
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.7
	us-gaap	Interest Paid InterestPaid	2048000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10668000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	137000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.4
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
	us-gaap	Net Income Loss NetIncomeLoss	7742000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.71
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35416000	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	0	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	46680000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	658000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	777000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	180000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11384000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11235000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11559000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10865000	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	2717000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2719000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	55000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5135000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4348000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2057000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6223000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3296000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	19000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-130000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	630000	USD
	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-329000	USD
	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-40000	USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-5225000	USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	1124000	USD
	anip	Increase Decrease Accrued Medicaid Rebates IncreaseDecreaseAccruedMedicaidRebates	2164000	USD
	anip	Increase Decrease Accrued Medicaid Rebates IncreaseDecreaseAccruedMedicaidRebates	1023000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1420000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	870000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12562000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11292000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31578000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	234000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	432000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	892000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48069000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18124000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23945000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11105000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35050000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	109000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2015Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	143750000	USD
CY2015Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	28557000	USD
CY2015Q3	us-gaap	Long Term Debt LongTermDebt	115193000	USD
CY2015Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1078000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3234000	USD
CY2015Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1521000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4502000	USD
CY2014Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	17000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	57000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	53000	USD
CY2015Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	211000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	633000	USD
CY2015Q3	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	11000	USD
	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	26000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4529000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6661000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	12417000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7645000	USD
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	179000	shares
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	67000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	207000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	41000	shares
CY2015Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4559000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	6746000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	12499000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	7742000	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	700000	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2200000	shares
CY2015Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	10563000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5056000	USD
CY2015Q3	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	1023000	USD
CY2014Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	794000	USD
CY2015Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	573000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	411000	USD
CY2015Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1775000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1368000	USD
CY2015Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	193000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	111000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4257000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3794000	USD
CY2015Q3	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	11000	USD
	us-gaap	Depreciation Depreciation	400000	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1900000	USD
CY2014Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2200000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1894000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7578000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7578000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7578000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7578000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	36085000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	500000	shares
CY2015Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	900000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2100000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2500000	USD
CY2014Q1	anip	Stock Issued During Period Due To Warrant Exercise Number StockIssuedDuringPeriodDueToWarrantExerciseNumber	20000	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.314	pure
CY2014Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.186	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.169	pure
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	200000	USD
CY2015Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	19000	USD
CY2015Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4500000	USD
CY2015Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	115193000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	110691000	USD
CY2015Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	9980000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	8708000	USD
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-40000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <b>Overview</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> ANI Pharmaceuticals, Inc. and its subsidiary, ANIP Acquisition Company (together, “ANI,” the “Company,” “we,” “us,” or “our”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Our targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. We have two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products that must be manufactured in a fully-contained environment. Our strategy is to use our assets to develop, acquire, manufacture, and market branded and generic specialty prescription pharmaceuticals. By executing this strategy, we believe we will be able to continue to grow the business, expand and diversify our product portfolio, and create long-term value for our investors.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10090000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9017000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2015Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.194	pure
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	4529000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	6662000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	12417000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	2799000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	8343000	USD
CY2015Q3	us-gaap	Inventory Gross InventoryGross	13934000	USD
CY2015Q3	us-gaap	Goodwill Gross GoodwillGross	1800000	USD
CY2014Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	600000	USD
CY2015Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	131400000	USD
CY2015Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000000	USD
	anip	Share Based Compensation Catch Up ShareBasedCompensationCatchUp	1300000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	76499000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	45999000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8208000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3932000	USD
CY2015Q3	anip	Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber	100000	shares
	anip	Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber	300000	shares
	anip	Contingent Payment For Asset Purchase ContingentPaymentForAssetPurchase	0	USD
	anip	Contingent Payment For Asset Purchase ContingentPaymentForAssetPurchase	1000000	USD
	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.15	pure
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Depreciation Depreciation	200000	USD
CY2014Q3	us-gaap	Depreciation Depreciation	200000	USD

Files In Submission

Name	View Source	Status
0001144204-15-062504-index-headers.html	Edgar Link	pending
0001144204-15-062504-index.html	Edgar Link	pending
0001144204-15-062504.txt	Edgar Link	pending
0001144204-15-062504-xbrl.zip	Edgar Link	pending
anip-20150930.xml	Edgar Link	completed
anip-20150930.xsd	Edgar Link	pending
anip-20150930_cal.xml	Edgar Link	unprocessable
anip-20150930_def.xml	Edgar Link	unprocessable
anip-20150930_lab.xml	Edgar Link	unprocessable
anip-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tex10-2logo.jpg	Edgar Link	pending
v421880_10q.htm	Edgar Link	pending
v421880_ex10-1.htm	Edgar Link	pending
v421880_ex10-2.htm	Edgar Link	pending
v421880_ex31-1.htm	Edgar Link	pending
v421880_ex31-2.htm	Edgar Link	pending
v421880_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI PHARMACEUTICALS INC Stock $anip

2015 Q3 Form 10-Q Financial Statement

#000114420415062504 Filed on November 03, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI PHARMACEUTICALS INC Stock $anip

2015 Q3 Form 10-Q Financial Statement

#000114420415062504 Filed on November 03, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI PHARMACEUTICALS INC Stock $anip